| Clinical data | |
|---|---|
| Other names | RG7351 |
| Drug class | Trace amine-associated receptor 1 (TAAR1)partial agonist |
RG-7351 is atrace amine-associated receptor 1 (TAAR1)partial agonist that is or was under development for the treatment ofmajor depressive disorder.[1][2][3][4] It reachedphase 1clinical trials for this indication in 2010.[1][2][4] However, as of November 2023, no further recent development has been reported since July 2016.[1] The drug was developed byHoffmann-La Roche.[1][2][4]
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |